Literature DB >> 8739244

Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts.

S Bartel1, B Stein, T Eschenhagen, U Mende, J Neumann, W Schmitz, E G Krause, P Karczewski, H Scholz.   

Abstract

Disturbances in the cAMP production during beta-adrenergic stimulation and alterations of Ca2+ transport controlling proteins and their regulation in the sarcoplasmic reticulum might be involved in the pathogenesis of the failing human heart. Thus, we investigated the cAMP-mediated phosphorylation of phospholamban, troponin I and C-protein in electrically driven, intact isolated trabeculae carneae from nonfailing and failing (NYHA IV) human hearts in parallel to contractile properties on the same tissue samples. The increase in force of contraction induced by isoproterenol (0.2 microM) or pimobendan (100 microM), a phosphodiesterase inhibitor, was diminished in the failing human hearts compared to nonfailing hearts by 49% and 36%, respectively. Concomitantly the isoproterenol-induced phosphorylation (pmol P/mg homogenate protein) of phospholamban, troponin I and C-protein was reduced from 13.0 +/- 2.4 (n = 4), 30.5 +/- 1.5 (n = 5) and 11.0 +/- 1.3 (n = 5) in the nonfailing heart to 5.2 +/- 0.6 (n = 13), 14.6 +/- 2.2 (n = 16) and 7.1 +/- 1.0 (n = 6) in the failing human heart, respectively. Pimobendan changed the phosphorylation state of these proteins similar to isoproterenol. The fact that combined addition of both agents or dibuturyl cAMP (1 mM) alone restored the phosphorylation capacity as observed in the control groups indicates that i) a reduced cAMP generation is related to the reduced phosphorylation of regulatory phosphoproteins located in the sarcoplasmic reticulum and contractile apparatus e.g. phospholamban, troponin I and C-protein, that ii) there is a relationship between protein phosphorylation state and contractile activity and that iii) no changes in the respective content of phosphoproteins are involved in the limitation of cAMP-mediated inotopic activity in the failing human heart.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8739244     DOI: 10.1007/bf00227896

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  30 in total

1.  Purification and complete sequence determination of the major plasma membrane substrate for cAMP-dependent protein kinase and protein kinase C in myocardium.

Authors:  C J Palmer; B T Scott; L R Jones
Journal:  J Biol Chem       Date:  1991-06-15       Impact factor: 5.157

2.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

3.  Altered expression of alpha-subunits of G proteins in failing human hearts.

Authors:  A M Feldman; A E Cates; M R Bristow; C Van Dop
Journal:  J Mol Cell Cardiol       Date:  1989-04       Impact factor: 5.000

4.  Differential sensitivity to isoprenaline of troponin I and phospholamban phosphorylation in isolated rat hearts.

Authors:  P Karczewski; S Bartel; E G Krause
Journal:  Biochem J       Date:  1990-02-15       Impact factor: 3.857

5.  Distribution of beta-adrenergic receptors in failing human myocardium. Implications for mechanisms of down-regulation.

Authors:  S S Murphree; J E Saffitz
Journal:  Circulation       Date:  1989-06       Impact factor: 29.690

6.  Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart.

Authors:  M Ungerer; G Parruti; M Böhm; M Puzicha; A DeBlasi; E Erdmann; M J Lohse
Journal:  Circ Res       Date:  1994-02       Impact factor: 17.367

7.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

8.  Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation.

Authors:  W Luo; I L Grupp; J Harrer; S Ponniah; G Grupp; J J Duffy; T Doetschman; E G Kranias
Journal:  Circ Res       Date:  1994-09       Impact factor: 17.367

9.  Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.

Authors:  M D Feldman; L Copelas; J K Gwathmey; P Phillips; S E Warren; F J Schoen; W Grossman; J P Morgan
Journal:  Circulation       Date:  1987-02       Impact factor: 29.690

10.  Reduced positive inotropic effects in diseased human ventricular myocardium.

Authors:  L Brown; B Lorenz; E Erdmann
Journal:  Cardiovasc Res       Date:  1986-07       Impact factor: 10.787

View more
  20 in total

1.  Type 1 phosphatase, a negative regulator of cardiac function.

Authors:  Andrew N Carr; Albrecht G Schmidt; Yoichi Suzuki; Federica del Monte; Yoji Sato; Carita Lanner; Kristine Breeden; Shao-Ling Jing; Patrick B Allen; Paul Greengard; Atsuko Yatani; Brian D Hoit; Ingrid L Grupp; Roger J Hajjar; Anna A DePaoli-Roach; Evangelia G Kranias
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

2.  Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium.

Authors:  Sabine Weninger; Joris H De Maeyer; Romain A Lefebvre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-03       Impact factor: 3.000

3.  Beta 2-adrenoceptor activation by zinterol causes protein phosphorylation, contractile effects and relaxant effects through a cAMP pathway in human atrium.

Authors:  A J Kaumann; L Sanders; J A Lynham; S Bartel; M Kuschel; P Karczewski; E G Krause
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

4.  PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients.

Authors:  Peter Molenaar; Torsten Christ; Rizwan I Hussain; Andreas Engel; Emanuel Berk; Katherine T Gillette; Lu Chen; Alejandro Galindo-Tovar; Kurt A Krobert; Ursula Ravens; Finn Olav Levy; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

5.  PDE4 in the human heart - major player or little helper?

Authors:  Thomas Eschenhagen
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

6.  Targeting of phospholamban by peroxynitrite decreases beta-adrenergic stimulation in cardiomyocytes.

Authors:  Mark J Kohr; Honglan Wang; Debra G Wheeler; Murugesan Velayutham; Jay L Zweier; Mark T Ziolo
Journal:  Cardiovasc Res       Date:  2007-09-19       Impact factor: 10.787

7.  Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality.

Authors:  Nicole Brüchert; Nirmala Mavila; Peter Boknik; Hideo A Baba; Larissa Fabritz; Ulrich Gergs; Uwe Kirchhefer; Paulus Kirchhof; Marek Matus; Wilhelm Schmitz; Anna A DePaoli-Roach; Joachim Neumann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-08       Impact factor: 4.733

Review 8.  Troponin I modulation of cardiac performance: Plasticity in the survival switch.

Authors:  Brandon J Biesiadecki; Margaret V Westfall
Journal:  Arch Biochem Biophys       Date:  2019-01-23       Impact factor: 4.013

Review 9.  Beta-adrenergic stimulation and myocardial function in the failing heart.

Authors:  Ali El-Armouche; Thomas Eschenhagen
Journal:  Heart Fail Rev       Date:  2009-12       Impact factor: 4.214

Review 10.  Tumor Necrosis Factor-α in Heart Failure: an Updated Review.

Authors:  Sarah M Schumacher; Sathyamangla V Naga Prasad
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.